# Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

> **NCT04152863** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 85 (actual)

## Conditions studied

- Advanced/Metastatic Melanoma

## Interventions

- **BIOLOGICAL:** Gebasaxturev IV
- **BIOLOGICAL:** Gebasaxturev ITu
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04152863
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-05
- **Primary completion:** 2023-07-12
- **Final completion:** 2023-07-12
- **Target enrollment:** 85 (ACTUAL)
- **Why stopped:** Business Reasons
- **Last updated:** 2024-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04152863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04152863, "Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04152863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*